Annovis Bio

$26.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.11%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Annovis Bio and other stocks, options, and ETFs commission-free!

About ANVS

Annovis Bio, Inc., also called Annovis Bio, is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders.

CEO
Maria-Luisa Maccecchini
Employees
2
Headquarters
Berwyn, Pennsylvania
Founded
2008
Market Cap
198.00M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
212.77K
High Today
$26.87
Low Today
$25.30
Open Price
$26.30
Volume
133.03K
52 Week High
$47.99
52 Week Low
$2.93

ANVS Earnings

-$0.34
-$0.23
-$0.11
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 4, Pre-Market

You May Also Like

OII
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure